期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

维格列汀有效控制空腹血糖和减少血糖波动:从基础到临床

Dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting plasma glucose with lower glycemic excursion:basic science to the clinic
暂未订购
导出
摘要 空腹血糖和血糖波动不仅描述血糖变化状况,也是影响2型糖尿病患者预后的重要指标。空腹血糖和血糖波动的改善将有效降低2型糖尿病发生微血管和大血管并发症的风险。新型口服降糖药维格列汀,因具有快速持久提供体内活性GLP-1水平和双向调节胰岛细胞分泌功能的独特机制,使其能够更好地控制空腹血糖和血糖波动。
作者 母义明
机构地区 解放军总医院内分泌科
出处 《药品评价》 CAS 2013年第13期42-44,共3页 Drug Evaluation
关键词 维格列汀 2型糖尿病 空腹血糖 血糖波动 预后
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献14

  • 1Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fastingglucose on cardiovascular disease: the Framingham Heart Study. J Am CollCardiol. 2008;51(3):264-70.
  • 2Boden-Albala B, Cammack S,Chong J, et al. Diabetes, fasting glucose levels,and risk of ischemic stroke and vascular events: findings from the NorthernManhattan Study (NOMAS). Diabetes Care. 2008;31(6): 1132-7.
  • 3Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk ofmicrovascular complications in type 1 diabetes: data from the Diabetes Controland Complications Trial. Diabetes Care. 2008;31(11 ):2198-202.
  • 4Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atheroscleroticprocess by control of daily acute glucose fluctuations in diabetic patients treatedby DPP-IV inhibitors. Atherosclerosis. 2013;227(2):349-54.
  • 5Hermanides J, Vriesendorp TM, Bosman RJ, et al. Glucose variability isassociated wifli intensive care unit mortality.
  • 6张儒雅,陆菊明.DPP-4抑制剂在2型糖尿病治疗中的应用[J].中华内分泌代谢杂志,2011,27(1):101-104. 被引量：75
  • 7Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of thedipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab.2011;13(9):775-83.
  • 8Davis JA, Singh S, Sethi S, et al. Nature of action of Sitagliptin, the dipeptidylpeptidase-IV inhibitor in diabetic animals. Indian J Pharmacol. 2010;42(4):229-33.
  • 9Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice dailyvs. sitagliptin once daily on 24-hour acute glucose fluctuations. J DiabetesComplications.2009;24:79-83.
  • 10He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ClinPharmacokinet. 2012;51 ⑶:147-62.

二级参考文献30

  • 1Goke B.Islet cell function:alpha and beta cells-partners towards normoglycaemia.Int J Clin Pract Suppl,2008,(159):2-7.
  • 2Kim MH,Lee MK.The incretins and pancreatic beta-cells:use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes Mellitus.Korean Diabetes J,2010,34:2-9.
  • 3Kim W,Egan JM.The role of incretins in glucose homeostasis and diabetes treatment.Pharmacol Rev,2008,60:470-512.
  • 4Neumiller JJ,Wood L,Campbell RK.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Pharmacotherapy,2010,30:463-484.
  • 5Deacon CF.Circulation and degradation of GIP and GLP-1.Horm Metab Res,2004,36:761-765.
  • 6Deacon CF,Carr RD,Holst JJ.DPP-4 inhibitor therapy:new directions in the treatment of type 2 diabetes.Front Biosci,2008,13:1780-1794.
  • 7Lankas GR,Leiting B,Roy RS,et al.Dipeptidyl peptidase Ⅳ inhibition for the treatment of type 2 diabetes:potential importance of selectivity over dipeptidyl peptidases 8 and 9.Diabetes,2005,54:2988 -2994.
  • 8Holst JJ,Deacon CF.Inhibition of the activity of dipeptidyl-peptidase Ⅳ as a treatment for type 2 diabetes.Diabetes,1998,47:1663-1670.
  • 9Ahren B,Holst JJ,Martensson H,et al.Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase Ⅳ in mice.Eur J Pharmacol,2000,404:239-245.
  • 10Mari A,Sallas WM,He YL,et al.Vildagliptin,a dipeptidyl peptidase-Ⅳ inhibitor,improves model-assessed beta-cell function in patients with type 2 diabetes.J Clin Endocrinol Metab,2005,90:4888-4894.

共引文献74

药品评价
2013年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部